AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase II clinical trial titled ‘A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn’s Disease and an Ileostomy (CALLISTO)’. The study aims to assess the safety, tolerability, and mucosal repair effects of AZD7798 compared to a placebo in patients with active ileal Crohn’s disease who have an ileostomy.
Intervention/Treatment: The study is testing AZD7798, an experimental drug, against a placebo. AZD7798 is designed to improve mucosal repair in Crohn’s disease patients.
Study Design: This interventional study uses a randomized, parallel assignment model. Participants are randomly assigned in a 2:1 ratio to receive either AZD7798 or a placebo during a 12-week blind induction period. After this, eligible participants enter a 40-week open-label maintenance period. The study employs triple masking, where the participant, care provider, and investigator are blinded to the treatment assignment.
Study Timeline: The study began recruiting on September 25, 2024. The last update was submitted on August 14, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential impact on treatment options.
Market Implications: The progress of this study could significantly influence AstraZeneca’s stock performance, as successful results may enhance investor confidence and market position in the competitive pharmaceutical industry. The study’s outcome could also impact competitors focusing on similar treatments for Crohn’s disease.
The study is currently ongoing, with further details available on the ClinicalTrials portal.